89bio, Inc. - Common Stock (OQ:ETNB)

Jan 05, 2021 08:00 am ET
89bio Provides Business Outlook for 2021
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including...
Jan 04, 2021 08:00 am ET
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Nov 24, 2020 08:00 am ET
89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Nov 13, 2020 08:00 am ET
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced updated data from its positive...
Nov 10, 2020 04:02 pm ET
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 02, 2020 08:00 am ET
89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH at AASLD’s The Liver Meeting® 2020
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that clinical data from its...
Sep 28, 2020 05:18 pm ET
89bio to Present at Upcoming Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Sep 23, 2020 07:00 am ET
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date,...
Sep 16, 2020 08:51 pm ET
89bio Announces Pricing of Upsized Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized...
Sep 14, 2020 05:21 pm ET
89bio Announces Proposed Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an...
Sep 14, 2020 07:01 am ET
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
89bio, Inc. (Nasdaq: ETNB) today announced positive topline results from its Phase 1b/2a trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH). All dose groups demonstrated significant...
Sep 13, 2020 07:53 pm ET
89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH
89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14,...
Sep 03, 2020 08:30 am ET
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of a Phase 2...
Aug 13, 2020 04:05 pm ET
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Aug 03, 2020 04:05 pm ET
89bio to Present at Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Jul 13, 2020 10:18 am ET
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the closing of its upsized...
Jul 07, 2020 09:30 pm ET
89bio Announces Pricing of Upsized Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized...
Jul 06, 2020 06:30 am ET
89bio Announces Proposed Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an...
Jun 04, 2020 08:00 am ET
89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S....
May 13, 2020 04:05 pm ET
89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
May 08, 2020 07:30 am ET
89bio to Present at Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Apr 13, 2020 08:30 am ET
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic...
Mar 25, 2020 04:05 pm ET
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven...
Mar 18, 2020 04:05 pm ET
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Feb 21, 2020 04:05 pm ET
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Dec 18, 2019 04:05 pm ET
89bio Reports Third Quarter 2019 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 13, 2019 04:02 pm ET
89bio Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its upsized...
Nov 11, 2019 09:25 am ET
89bio Announces Presentations of BIO89-100 Data at The Liver Meeting® 2019
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its investigational therapy, BIO89-100, will be presented today at The Liver Meeting 2019, the annual meeting of the American Association...
Nov 11, 2019 08:22 am ET
89bio Announces Pricing of Upsized Initial Public Offering
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its upsized...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.